Search results
- (-) Remove Press releases filter Press releases
GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents
Oxford, UK – 28 October 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy
Oxford BioMedica: Notice of Interim Results Results date: 27 August 2015
Oxford, UK – 6 August 2015: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading gene and cell therapy group, will be announcing its i
Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London
Oxford, UK – 23 June 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy gr
Oxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York
Oxford, UK – 29 May 2015: Oxford BioMedica plc (LSE: OXB) (“the Group”), a leading gene and cell therapy group, today announces th
Oxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group
Oxford BioMedica Interim Management Statement
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group” or “OXB”) (LSE:OXB), a leading gene and cell ther
Oxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research in Vision and Ophthalmology conference in US
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene and cell therapy based biopharmaceutica